Hongri Chen1, Weiqiang Dou2, and Wei yin Liu2
1Dalian Medical University, Northern Jiangsu People’s Hospital, Yangzhou, China, Yangzhou, China, 2GE Healthcare, MR Research China, Beijing, P.R. China, Beijing, China
Synopsis
The present study was to
explore regional perfusion changes in patients with Parkinson's disease
dementia (PDD) and Alzheimer’s disease (AD) using 3D arterial spin labeling MRI
and further assess the corresponding difference between PDD and AD patients. The
results revealed
that the perfusion pattern in PDD group was distinct from that in AD group despite
of overlapped perfusion regions. The resultant normalized cerebral blood flow (CBF)
can distinguish PDD from AD. Therefore, normalized CBF
provided sensitive imaging-based markers that contribute to the diagnosis and differential
diagnosis of the two dementia.
Introduction
Parkinson's disease (PD)
is a progressive movement disorder characterized by loss of dopaminergic
neurons in the substantia nigra. 10% of PD patients develop PD dementia (PDD)1
annually. In comparison, Alzheimer’s
disease (AD) is characterized by the deposition of beta-amyloid (plaques) and
tau protein (neurofibrillary tangles) as the central pathological features2.
Cognitive impairment (CI) has been found in both AD and PDD patients. However, it
remains difficult to differentiate both diseases based on clinical CI evaluation.
3D arterial spin
labeling (ASL) MRI, as a well-established method, is able to measure cerebral
blood perfusion quantitatively. ASL derived absolute cerebral blood flow (CBF)
has been widely applied to early diagnosis and evaluation of treatment effect
for AD and PD patients. However, A recent study reported that a further normalized
CBF is able to provide more sensitive perfusion pattern than absolute CBF,
being comparable to PET-derived PD motor-related pattern (PDRP)3. Therefore, the main goal
of this study was to investigate if normalized CBF was sufficiently sensitive
to detect changes in perfusion between PDD and AD.Materials and Methods
24 patients with AD (17
men and 7 women, mean age: 68.95±6.97 years), 26 patients with PDD (18 men and 8
women, mean age: 66.50±7.01) and 35 controls (18 men and 17 women, mean age:
62.75±3.50 years) underwent a routine brain MRI, 3D pseudo-continuous (pc)ASL
and neuropsychological tests, including MMSE and MoCA for global cognitive
functions. Moreover, memory, attention, executive function, visual space
function, and language related tests in turn. The UPDRS-III and the H &Y
stages were used to assess motor function of PDD patients.
All
MR imaging was acquired on a 3.0 Tesla (Discovery MR750, GE, USA) with 8 coil
employed.
3D
pcASL imaging was acquired with the following parameters: TR = 4844 ms, TE = 5.1
ms, post labeling delay = 2025 ms, FOV = 240 mm × 240 mm, matrix size = 64x64,
4 mm slice thickness and 0 mm gap slice space, NEX =3. The scan time was 4
minutes 41 seconds. For anatomic location and volume correction, a
high-resolution 3D anatomical T1 weighted brain volume imaging (3D-BRAVO) were
collected.
Data
analysis
3D pcASL data were
analyzed using a vendor-provided post-processing software in GE ADW4.6
workstation. The whole brain CBF parametric mapping was obtained accordingly
for each subject. The CBF maps and T1 images were preprocessed
using SPM 12 software. After registration, normalization and smoothing,
absolute CBF maps are obtained. Normalized
CBF maps were obtained by dividing the CBF maps by the subject-specific whole
brain mean CBF value for each subject. ANCOVA analysis was
conducted on the absolute and normalized CBF maps of AD, PDD, and HC with age,
gender, education level, and gray matter volumes as covariates, followed by
post hoc two sample t tests. Then, between group two sample t tests were
performed within the mask showing conspicuous differences acquired from ANCOVA
analysis (P < 0.001, FWE corrected for multiple comparisons).
We
also correlated regional CBF values with cognitive and motor assessment scores,
and all significant brain areas were among the changed results between AD group
and PDD group. All statistical analyses were performed in SPSS 25.0 software, the
significance threshold of correlation analysis was set at P <0.05. Receiver operating characteristic (ROC) analysis was
constructed on MedCalc 15.6 software to ascertain the recognition capacity
efficacy of normalized CBF to discriminate AD from PDD patients.Results
There was no evidence of
absolute CBF difference among three groups. Normalized CBF reflected overlapped
patterns of cortical hypoperfusion and subcortical hyperperfusion between AD
and PDD group (Fig 1). AD patients had more extensive perfusion deficits in cognitive
related areas (right middle temporal gyrus (MTG) and precuneus) than PDD
patients. As compared with AD patients, the hypoperfusion of PDD patients
mainly located in the subcortical and motor-related brain regions (right (supplementary motor area)
SMA and bilateral putamen) (Fig 2).
In
AD group, the MMSE scores were positively correlated with the normalized CBF of
the right precuneus and right middle temporal gyrus (P=0.033, r=0.442; P=0.012,
r=0.503), and the memory scores were positively correlated with the normalized
CBF of the right precuneus (P=0.049,r=0.406). The UPDRS-III
scores showed positive relationship with normalized CBF of the right
putamen (P=0.017, r=0.214) in PDD group (Fig 3). ROC analysis
showed normalized CBF had good sensitivity and specificity to discriminate AD
patients from PDD patients (Fig 4). Discussion and conclusion
The
results are consistent with previous studies4, no statistically
significance of perfusion difference between AD and PDD was found by using
absolute CBF. However, the regional perfusion patterns of AD and PDD using
normalized CBF was in accordance with the identified patterns using spatial
covariance analysis of 18F-fluorodeoxyglucose (FDG)-PET5,6.The significant
difference of normalized CBF values in specific regions between the two groups,
and significant correlations of normalized CBF values and characteristics scores
in these regions were revealed in our study.
Therefore, the
normalized CBF might be considered to have clinical potential to explore
functional changes between AD and PDD patients and reflect the perfusion differences
of specific brain regions in corresponding to their own pathological changes
between diseases. Acknowledgements
This work was supported by the National Natural Science Foundation of China (Grant NO: 81471642). We greatly thank Dr. Songan Shang and Weiyin Vivian Liu for their comments on the manuscript writing, and Dr. Hongying Zhang for her methodological guidance.References
1. GOETZ CG, EMRE M, DUBOIS B. Parkinson's
disease dementia: Definitions, guidelines, and research perspectives in
diagnosis [J]. Annals of Neurology, 2010, 64.
2. LONG J, HOLTZMAN D. Alzheimer Disease: An
Update on Pathobiology and Treatment Strategies [J]. Cell, 2019, 179: 312-339.
3. S R, N K, J O, et al. Arterial spin labeling
detects perfusion patterns related to motor symptoms in Parkinson's disease
[J]. Parkinsonism & related disorders, 2020, 76: 21-28.
4. LE HERON CJ, WRIGHT SL, MELZER TR, et al.
Comparing cerebral perfusion in Alzheimer's disease and Parkinson's disease
dementia: an ASL-MRI study [J]. J Cereb Blood Flow Metab, 2014, 34: 964-970.
5. HABECK C, FOSTER N, PERNECZKY R, et al.
Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease [J].
NeuroImage, 2008, 40: 1503-1515.
6. MA Y, TANG C, SPETSIERIS P, et al. Abnormal
metabolic network activity in Parkinson's disease: test-retest reproducibility
[J]. Journal of cerebral blood flow and metabolism : official journal of the
International Society of Cerebral Blood Flow and Metabolism, 2007, 27: 597-605.